Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate o...
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate o...
New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations i...
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in ...
8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy...
Jefferies analyst Matthew Taylor initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces ...
The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation therapy (also known as...
